Positioning of the drug within the HIV approved drug landscape.
This means the next trial will not be targeting cure. Immune benefits for long term patients looks much more likely as the current/next target.
No reason why they can’t do this in Australia and take advantage of the massive help our government is offering in clinical trial funding.
DYOR
Positioning of the drug within the HIV approved drug landscape....
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
-0.001(5.00%) |
Mkt cap ! $17.14M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.9¢ | $5.671K | 298.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 512798 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.0¢ | 1050263 | 5 |
View Market Depth
| Last trade - 15.59pm 04/10/2024 (20 minute delay) ? |
| BIT (ASX) Chart |